Cardiovascular System Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/31

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary review of cardiovascular pharmacology, including antihypertensives, heart failure drugs, antiarrhythmics, antianginals, lipid-lowering agents, anticoagulants, and anemia treatments.

32 Terms

1
New cards

Angiotensin-Converting Enzyme (ACE) Inhibitors

A class of antihypertensive drugs typically ending in '-pril' that act in the lungs to prevent the conversion of angiotensin I to angiotensin II, decreasing aldosterone production, lowering blood pressure, increasing serum potassium, and promoting sodium and fluid loss.

2
New cards

Angiotensin II Receptor Blockers (ARBs)

A class of antihypertensive medications typically ending in '-sartan' that selectively bind to angiotensin II receptors in vascular smooth muscle and the adrenal cortex to prevent vasoconstriction and block the release of aldosterone.

3
New cards

Direct Renin Inhibitor

A class represented by aliskiren (Tekturna) that directly inhibits renin, decreasing plasma renin activity and preventing the conversion of angiotensinogen to angiotensin I to manage essential hypertension.

4
New cards

Calcium-Channel Blockers (CCBs)

Medications typically ending in '-ipine' (along with verapamil and diltiazem) that inhibit calcium movement across myocardial and arterial muscle cell membranes, altering action potentials and blocking contraction to reduce blood pressure, cardiac workload, and myocardial oxygen consumption.

5
New cards

Nonselective Beta-Adrenergic Blocking Agents

Medications ending in '-olol' (such as propranolol, nadolol, and timolol) that competitively block beta-adrenergic receptors throughout the sympathetic nervous system, including cardiac beta-receptors, nephron juxtaglomerular cells, and bronchial smooth muscle.

6
New cards

Beta1-Selective Adrenergic Blocking Agents

Cardioselective agents ending in '-olol' (such as atenolol, metoprolol, and esmolol) that preferentially block beta1-receptors in the heart and juxtaglomerular apparatus at therapeutic doses, making them preferred for patients who smoke or have chronic obstructive pulmonary disease.

7
New cards

Vasodilators

Medications such as hydralazine, minoxidil, and nitroprusside that act directly on vascular smooth muscle to produce relaxation, rapid vasodilatation, and blood pressure reduction, primarily reserved for severe or refractory hypertension and emergencies.

8
New cards

Heart Failure (HF)

A condition in which structural and/or functional irregularities in the heart prevent it from effectively pumping sufficient blood throughout the body, resulting in low cardiac output.

9
New cards

Cardiac Glycosides

A drug class represented by digoxin (Lanoxin) that increases intracellular calcium entry during myocardial depolarization, leading to increased force of contraction, increased cardiac output, slowed heart rate, and decreased conduction velocity.

10
New cards

Digoxin Therapeutic Range

The traditional textbook serum concentration cited as 0.5–2.0 ng/mL0.5\text{--}2.0\,\text{ng/mL}, where levels below 0.5 ng/mL0.5\,\text{ng/mL} may be subtherapeutic and levels above 2.0 ng/mL2.0\,\text{ng/mL} carry heightened risk for toxicity.

11
New cards

Class 0 Antiarrhythmics

A category of antiarrhythmics represented by ivabradine (Coralan, Corlanor) that acts by blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.

12
New cards

Class Ia Antiarrhythmics

Sodium channel blockers such as disopyramide, procainamide, and quinidine that depress phase 0 of the action potential and prolong the overall action potential duration.

13
New cards

Class Ib Antiarrhythmics

Sodium channel blockers such as lidocaine and mexiletine that depress phase 0 somewhat and shorten the duration of the cardiac action potential.

14
New cards

Class Ic Antiarrhythmics

Sodium channel blockers such as flecainide and propafenone that markedly depress phase 0, producing extreme slowing of conduction with little effect on action potential duration.

15
New cards

Class Id Antiarrhythmics

Antiarrhythmic agents represented by ranolazine (Ranexa) that inhibit the late sodium current occurring after the rapid influx of sodium during an action potential.

16
New cards

Class II Antiarrhythmics

Beta-adrenergic blockers, including acebutolol, esmolol, and propranolol, that block sympathetic stimulation in cardiac tissue to manage arrhythmias.

17
New cards

Class III Antiarrhythmics

Potassium channel blockers such as amiodarone, dofetilide, ibutilide, and sotalol that prolong the refractory period and cardiac action potential duration.

18
New cards

Class IV Antiarrhythmics

Calcium-channel blockers represented by diltiazem and verapamil that slow conduction through the atrioventricular (AV) node to control cardiac rhythm.

19
New cards

Stable Angina

Chest discomfort occurring with no underlying permanent damage to the heart muscle, where basic physiological reflexes surrounding the pain restore myocardial blood flow.

20
New cards

Unstable Angina

A form of ischemic heart disease characterized by episodes of myocardial ischemia and chest pain occurring even when the patient is at rest.

21
New cards

Prinzmetal Angina

Angina pectoris caused by spasm of the coronary blood vessels rather than mechanical vessel narrowing alone.

22
New cards

Nitrates

Antianginal agents such as nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate that act directly on smooth muscle to cause relaxation, dilate veins, arteries, and capillaries, and decrease blood pressure to relieve myocardial oxygen demand.

23
New cards

Bile Acid Sequestrants

Lipid-lowering agents including cholestyramine, colestipol, and colesevelam that bind bile acids directly within the intestine to create an unabsorbable complex excreted in feces.

24
New cards

HMG-CoA Reductase Inhibitors

Lipid-lowering medications ending in '-statin' that block 3-hydroxy-3-methylglutaryl-coenzyme A reductase, impeding cholesterol synthesis to lower LDL levels and modestly raise HDL levels.

25
New cards

Antiplatelet Agents

Medications such as aspirin, clopidogrel, and ticagrelor that block receptor sites on platelet membranes to inhibit platelet adhesion and aggregation, preventing formation of the platelet plug.

26
New cards

Anticoagulants

Medications such as heparin, warfarin, dabigatran, and apixaban that interfere with the normal cascade of blood coagulation to prevent thrombus formation and propagation.

27
New cards

Protamine Sulfate

The specific reversal agent and antidote used exclusively to counteract the blood-thinning anticoagulant effects of heparin.

28
New cards

Vitamin K

The clinical antidote and reversal agent administered to counteract the anticoagulant action of warfarin (Coumadin).

29
New cards

Thrombolytic Agents

Medications such as alteplase, reteplase, and tenecteplase that stimulate the conversion of plasminogen to plasmin to actively dissolve preexisting intravascular clots in conditions such as acute ischemic stroke, STEMI, and pulmonary embolism.

30
New cards

Erythropoiesis-Stimulating Agents (ESAs)

Synthetic drugs (such as epoetin alfa and darbepoetin alfa) that act like natural erythropoietin to stimulate red blood cell synthesis in the bone marrow, targeting a maximum hemoglobin of 11 g/dL11\,\text{g/dL}.

31
New cards

Iron Deficiency Anemia Agents

Oral (such as ferrous sulfate and ferrous gluconate) or parenteral (such as iron sucrose and iron dextran) formulations administered to elevate serum iron concentration for hemoglobin synthesis.

32
New cards

Megaloblastic Anemia Agents

Essential replacement agents consisting of folic acid formulations and vitamin B12 compounds (hydroxocobalamin, cyanocobalamin) required for DNA synthesis, red blood cell stroma production, and nervous system myelin maintenance.